Trevi Therapeutics logo
Trevi Therapeutics
TRVI | NASDAQ
Chart Builder DCF Calculator
$13.29
-$0.36 (-2.64%)
At close: Nov 16, 2026, 4:00 PM ET
$13.29
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:38 PM ET

Trevi Therapeutics Company Profile

Company profile explained

Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Key Executives

Name Position
Jennifer L. Good Co-Founder, Chief Executive Officer, President & Director
David C. Hastings Chief Financial Officer & Principal Financial Officer
Christopher Galletta Controller & Chief Accounting Officer
Farrell Simon Chief Commercial Officer
James V. Cassella Chief Development Officer
Katie McManus Communications Manager
Thomas R. Sciascia Co-Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 17, 2026 4 Filing
Aug 06, 2026 S-8 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 06, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 04, 2026 4 Filing
Jun 04, 2026 8-K Current Report
Jun 04, 2026 4 Filing
Jun 04, 2026 4 Filing
View All SEC Filings ➞
Trevi Therapeutics
Trevi Therapeutics logo
Country United States
IPO Date May 7, 2019
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Jennifer L. Good

Contact Details

195 Church Street New Haven, Connecticut 06510 United States

Stock Details

Ticker Symbol TRVI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001563880
CUSIP Number 89532M101
ISIN Number US89532M1018
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.